News | May 17, 2023
Farxiga’s expanded approval highlights potential to differentiate in HF space, says GlobalData
Farxiga is expected to have such a strong influence on the market due to the impressive results
Farxiga is expected to have such a strong influence on the market due to the impressive results
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
This sBLA submission is supported by clinical, pre-clinical, and manufacturing data demonstrating the safety, tolerability, and immunogenicity of the bivalent vaccine.
Clinical studies are expected to start in Q2 2023.
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Subscribe To Our Newsletter & Stay Updated
